Biotech Values

[vinmantoo]

If you think the company has assets with value and is managed well as I do then the share price is silly, but it could be a tumultuous couple of weeks ahead

I sometimes underestimate how much fear and greed drive the markets, especially in the short-term. Nothing has changed with regards to the EDP-235 data, that it was able to reduced symptoms in a low-risk population, which is something that Paxlovid failed to do. Hopefully, ENTA will provide some clarity regarding their discussions with the FDA for the EDP-235 phase 3 trials in their 4 upcoming investor conferences this month.

The first conference is tomorrow Sept 7.

Wells Fargo Securities Healthcare Conference: Fireside Chat at 2:15 p.m. ET on September 7, 2023

https://finance.yahoo.com/news/enanta-pharmaceuticals-participate-investor-conferences-110000376.html